Effect of oral probiotic in the treatment of psoriasis
- Conditions
- psoriasis.psoriasis vulgarisL40.0
- Registration Number
- IRCT20140212016557N8
- Lead Sponsor
- Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Plaque type psoriasis
18 years of age or older
Involvement of 20% or less of body surface area
Severe scalp psoriasis
Worsening of signs and symptoms of psoriasis during treatment
Pregnancy
Lactation
Consumption of any systemic treatment affecting psoriasis within the last three months before recruiting in the study
Antibiotic administration within the recent two weeks
Any signs and symptoms of bacterial infections
Concomitant skin diseases
Presence of significant liver diseases
Presence of significant chronic kidney diseases
Consumption of probiotic-containing products (including probiotic-containing foods)
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Quantitative score of the clinical severity of psoriasis. Timepoint: At the beginning of treatment, months 1, 2, and 3 after treatment. Method of measurement: Psoriasis Area Severity Index (PASI) score.
- Secondary Outcome Measures
Name Time Method Qualitative clinical severity of psoriasis. Timepoint: Months 1, 2, and 3 after treatment. Method of measurement: Physician global assessment score.;Quality of life. Timepoint: At the beginning and end of treatment. Method of measurement: Dermatology quality of life index questionnaire.;Percentage of acceptable improvement. Timepoint: Months 1, 2, and 3 after treatment. Method of measurement: Percentage of people who achieve equal to or more than ??% reduction in Psoriasis Area Severity Score.;Rate of improvement. Timepoint: Months 1, 2, and 3 after treatment. Method of measurement: Time of achievement of equal to or more than ??% reduction in Psoriasis Area Severity Score.